The hypertension paradox was described over 10 years ago to stress the growing incidence of hypertension despite the availability of safe, effective, and inexpensive drug therapies.1 Multiple factors contribute to the hypertension paradox, including lack of patient awareness and education, failure to adhere to prescribed lifestyle changes and prescribed drug regimens, aging societal demographics, and recent recommendations for lowered blood pressure goals. Hence, a rationale exists for procedural-based therapy options that could augment drug therapy regimens and help more patients achieve and sustain blood pressure goals.

Percutaneous renal denervation has gained continued scientific and clinical interest due to its proven impact on autonomic function, likely because of both effferent and afferent mechanisms affecting the renal nerves.2 Clinical evidence suggests a strong association between renal denervation and reduced indices of sympathetic tone including muscle sympathetic nerve activity and renal norepinephrine spillover.3 Historically, surgical sympathetic denervation was shown to improve mortality, independent of its effect on blood pressure.4 In 2014, the randomized sham-controlled SYMPLICTY HTN-3 trial reported blood pressure drops in the renal denervation-treated group which were nearly matched by those in the sham control group.5 More recently however, 3 new multicenter, international, prospective, randomized, sham-controlled clinical trials have demonstrated lower blood pressure after catheter-based renal denervation in uncontrolled hypertensive patients in both the presence and absence of concomitant drug therapy,6-8 confirming the biological proof of principle. These trials have rekindled scientific and clinical interest in the procedure and have also revealed interesting new insights into the 24-hour profile of blood pressure reduction associated with the therapy. This review highlights the 24-hour circadian pattern of blood pressure lowering after renal denervation and hypothesize how these effects might complement drug therapy.

24-Hour Blood Pressure Monitoring: Toward Perfect Control

The advent of 24-hour ambulatory monitoring has allowed consideration of blood pressure as a continuous and dynamic circadian physiological signal, especially highlighting the unique blood pressure characteristics of the nighttime and early morning period. Thus, blood pressure control has been more meaningfully redefined relative to specific times of day9 (Figure 1). Circadian blood pressure variability is a direct reflection of the relative integrity of the autonomic nervous system which modulates its behavior. Multiple clinical trials have demonstrated that elevated nighttime blood pressure is more strongly associated with cardiovascular risk than daytime or office blood pressure.10,11 Furthermore, 24-hour blood pressure patterns distinguish between different hypertension phenotypes including white coat, masked and sustained hypertension as well as identifying abnormal nighttime dipping patterns. Recently, an analysis of the Spanish Ambulatory Blood Pressure registry with >60000 patients enrolled, indicated that white-coat hypertension, defined by an out of office 24-hour ambulatory blood pressure lower than goal blood pressure and in-office blood pressure that was above goal in unmedicated patients, was associated with increased mortality, and that masked hypertension was associated with a greater risk of death than sustained hypertension.12 Indeed, out of office ambulatory (ABPM) or home blood pressure measurement is now recommended to confirm the diagnosis of hypertension and, in the case of home blood pressure measurement, to monitor therapy efficacy in both the United States and European Hypertension Guidelines.13-17 Despite these recommendations, ABPM monitoring is used relatively rarely in clinic to confirm the diagnosis of hypertension, even among patients treated by hypertension specialists. Likewise, only recently has ambulatory blood pressure become the focus end point for clinical trials.18 Ideal blood pressure control includes 24-hour control, adequate circadian rhythm, and appropriate

From the Departments of Cardiovascular Medicine and Sleep and Circadian Cardiology, Jichi Medical University School of Medicine, Tochigi, Japan (K.K.); SUNY Downstate College of Medicine, Brooklyn, NY (M.A.W.); Department of Internal Medicine III, University Hospital of Saarland, Saarland University, Homburg/Saar, Germany (F.M., M.B.); Piedmont Heart Institute, Atlanta, GA (D.E.K.); Department of Nephrology and HTN, University Hospital of the Friedrich-Alexander University Erlangen-Nürnberg, Germany (R.E.S.); Center for Interventional Vascular Therapy, Columbia University Medical Center/New York-Presbyterian Hospital, and the Cardiovascular Research Foundation, New York (A.J.K.); Medtronic PLC, Santa Rosa, CA (D.A.H.); Perelman School of Medicine, University of Pennsylvania (R.R.T.); National and Kaposidistrian University of Athens, Hippocratie Hospital, Athens Medical Center, Greece (K.P.T.). Correspondence to Kazuomi Kario, Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, 3311-1, Yakushiji, Shimosuke, Tochigi 329-0498, Japan. Email kkario@jichi.ac.jp (Hypertension. 2019;74:244-249. DOI: 10.1161/HYPERTENSIONAHA.119.13081.) © 2019 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made. Hypertension is available at https://www.ahajournals.org/journal/hyp DOI: 10.1161/HYPERTENSIONAHA.119.13081

244
blood pressure variability with the goal of eliminating cardio-
vascular events.

**Prognostic Importance of Controlling Morning Blood Pressure**

Hypertensive cardiovascular risk including myocardial infarc-
tion, stroke, and sudden death is the highest during the morn-
ning surge period between 6 AM and 10 AM\(^9,20\) and the risk may
be even higher than for nighttime hypertension.\(^{21,22}\) Morning
hypertension might be caused by overactivation of the sym-
pathetic nervous system and can be modified by other sensory
inputs and by posture.\(^23\) Other factors, including arterial stiff-
ness and endothelial function also may play a role. The recent
J-HOP trial (Japan Morning Surge-Home Blood Pressure) of
4310 elderly patients with high cardiovascular risk showed
a positive linear association between home morning systolic
blood pressure (SBP) and cardiovascular events, especially
stroke. However, such an association was not observed for ei-
ther clinic SBP or home evening systolic pressure.\(^24\) Likewise,
the HONEST trial (Home Blood Pressure Measurement
with Olmesartan Naive Patients to Establish Standard Target
Blood Pressure) of over 21 000 hypertensive patients reported
increased risk for a cardiovascular event among patients with
home-measured morning SBP ≥150 mm Hg as compared with
the group with <125 mm Hg (HR, 5.03; 95% CI, 3.05–8.31).\(^25\)
Interestingly, even patients with normal office SBP were still
at risk if the morning home blood pressure was uncontrolled
(Figure 2). Furthermore, a pooled analysis of 5645 from the
International Database of Ambulatory Blood Pressure in
Relation to Cardiovascular Outcome reported that morning
surge SBP above the 90th percentile independently predicted
cardiovascular outcomes.\(^11\) Taken together, these and other tri-
als highlight the importance of home blood pressure monitor-
ing to effectively diagnose morning hypertension and titrate
hypertensive therapy dosage and timing accordingly.

**Effects of Percutaneous Renal Denervation Therapy on 24-Hour Blood Pressure Patterns**

The renal denervation procedure has the potential to aug-
ment standard antihypertensive drug therapy regimens and
may be especially useful if the drug regimen is suboptimal
or not well adhered to by the patient. The proposed mech-
anism by which renal denervation lowers blood pressure may
lend itself well to consistent 24-hour blood pressure control
(Figure 3). Reducing efferent neural traffic from the brain to
the kidney may particularly impact nighttime hypertension as
increasing renal blood flow and sodium excretion may restore
normal dipping patterns. Likewise, interrupting sensory affer-
tent signals from the kidney to the brain may reduce central
sympathetic nerve activity and increase baroreceptor sensor
sensitivity, thereby attenuating the morning surge.

Reports of the impact of renal denervation on nocturnal
blood pressure dipping patterns are mixed. Although some trials have reported improvements in nocturnal dipping status
after renal denervation,\(^26,27\) several nonrandomized\(^{28–32}\) as well
as randomized controlled studies\(^{33–35}\) failed to show an impact

![Figure 1. Cartoon diagram of the sympathetically modulated 24-h circadian pattern of blood pressure changes including nighttime dipping and the pre and postawakening morning blood pressure surge.](image)

![Figure 2. HONEST trial (Home Blood Pressure Measurement with Olmesartan Naive Patients to Establish Standard Target Blood Pressure) data indicating that low-office blood pressure may still be associated with high-morning blood pressure\(^5\) and increased cardiovascular risk. Hazard ratios for the incidence of cardiovascular events was the highest in the patients with morning home systolic blood pressure (SBP) ≥145 mm Hg and office SBP ≥150 mm Hg followed by patients with morning home SBP ≥145 and office SBP <130 mm Hg. The subgroup with morning home SBP <125 and office SBP <130 mm Hg was defined as a reference. Orange highlighted bars emphasize statistical significance vs the reference group. Reprinted with permission from Kario K, Saito I, Kushiro T, Teramukai S, Ishikawa Y, Mori Y, Kobayashi F, and Shimada K. Home blood pressure and cardiovascular outcomes in patients during antihypertensive therapy: primary results of HONEST, a large-scale prospective, real-world observational study. *Hypertension*. 2014;64:989–996. Copyright ©2014, Wolters Kluwer Health, Inc.)](image)
of renal denervation on nocturnal dipping patterns. However, these results may be due in part to nonspecific definitions and modest reproducibility of baseline dipping status. Indeed, recently published analyses support the hypothesis that the effects of renal denervation are apparent throughout the 24-hour period including during the nighttime and morning surge period. Several single and multicenter analyses of patients with treatment-resistant hypertension showed that the amplitude of the morning blood surge decreased after renal denervation. Notably, the SYMPLICITY HTN-3 trial showed no significant difference between blood pressure reduction in the denervation versus sham groups over the nighttime period nor was there a difference in the slope of the morning blood pressure surge between the denervation and sham-controlled groups. However, analysis of ambulatory SBP data from SYMPLICITY HTN-3 revealed that patients treated with renal denervation experienced a significantly greater change in morning (−7.3±19.8 mm Hg; P<0.001) and nighttime (defined from 1 AM to 6 AM; −6.1±18.2 versus −1.6±19.7 mm Hg; P=0.02) but not daytime SBP (−7.2±16.2 versus −6.4±18.6 mm Hg; P=0.67) as compared with control, and this finding was consistent when the SYMPLICITY HTN-3 results were pooled with the SYMPLICITY HTN-Japan study. This observation is now corroborated by the results of both the SPYRAL HTN OFF and ON MED trials that also showed greater between group blood pressure drops during nighttime versus daytime.

Additional insight to the mechanism of the 24-hour effects of renal denervation on blood pressure may be derived by examining hourly blood pressure changes (Figure 4). Unique patterns of 24-hour blood pressure reduction were recently reported in the randomized sham-controlled SPYRAL HTN-OFF trial at 3 months and the SPYRAL HTN-ON MED trial at 6 months. The observed reductions in 24-hour blood pressure were not present in the sham control group. Likewise, the recent RADIANCE HTN-SOLO clinical trial of renal denervation using an ultrasound-based catheter in uncontrolled hypertensive patients not taking antihypertensive medications reported similar patterns of blood 24-hour blood pressure reduction after 2 months, and these reductions were maintained out to 6 months after titration of drug therapy in those patients not initially achieving blood pressure control. In addition, a recent analysis of the long-term results of the SYMPLICITY HTN-Japan trial showed a shift in the 24-hour SBP curve versus baseline in the combined renal denervation and crossover group at 6 months as compared with the original untreated control group (Figure 4). The results in aggregate support the concept that denervation therapy is always on, providing cardiovascular protection throughout the day and the nighttime including the high-risk morning surge period. This action may result in consistently lower BP levels throughout the day and night and may thus partially compensate for the relative peaks and troughs of plasma drug concentrations because of pharmacokinetics and variable dosing times as well as drug nonadherence. More consistent 24-hour blood pressure control could have a critical positive impact on long-term clinical outcome.

Interestingly, the impact of denervation may also extend to 24-hour patterns of heart rate, another index of cardiovascular risk. A recently published analysis of the SPYRAL HTN OFF-MED trial showed that renal denervation lowered heart rate compared with sham, and these reductions were more apparent in the morning than during the day. The complex relationship between denervation therapy and the patterns of blood pressure and heart rate require additional investigation.

**Summary and Conclusions**

Ambulatory blood pressure is a better predictor of cardiovascular risk compared with office blood pressure, especially during nighttime and early morning periods, and is recommended to confirm hypertension diagnosis. Currently prescribed drug regimens make it challenging to achieve optimal 24-hour blood pressure control, especially in less adherent patients. New evidence on the 24-hour blood pressure reductions associated with renal denervation, coupled with the limitations of daily oral drug dosing, may improve blood pressure control when multiple therapy strategies, including procedures, drugs, and lifestyle changes are combined. Multiple independent trials demonstrate that renal denervation provides 24-hour blood pressure lowering including during the early morning high-risk period. Whether the documented blood pressure-lowering effects are persistent through long-term follow-up and lead to improved cardiovascular end points must be investigated in future clinical studies. Currently, several larger-scale randomized sham-controlled clinical trials of renal denervation in both
the presence and absence of antihypertensive medications are underway that will further enhance our understanding of the patterns of 24-hour blood pressure reduction associated with this novel therapy option. These studies should help define new care pathways that integrate drug and device-based strategies in this era of the hypertension paradox.
31. Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. *Circulation*. 2013;128:132–140. doi: 10.1161/CIRCULATIONAHA.112.000949

32. Ott C, Mahfoud F, Schmid A, Ditting T, Sobotka PA, Veelken R, Spies A, Ukena C, Laufs U, Uder M, Böhm M, Schmieder RE. Renal denervation in moderate treatment-resistant hypertension. *J Am Coll Cardiol*. 2013;62:1880–1886. doi: 10.1016/j.jacc.2013.06.023

33. Bakris GL, Townsend RR, Liu M, Cohen SA, D’Agostino R, Flack JM, Kandzari DE, Katzen BT, Leon MB, Mauri L, Neogita M, O’Neill WW, Oparil S, Rocha-Singh K, Bhatt DL. SYMPLICITY HTN-3 Investigators. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. *J Am Coll Cardiol*. 2014;64:1071–1078. doi: 10.1016/j.jacc.2014.05.012

34. Desch S, Okon T, Heinemann D, Kulle K, Röhnert K, Sonnabend *M*, Petzold M, Müller U, Schuler G, Eitel I, Thiele H, Lurz P. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. *Hypertension*. 2015;65:1202–1208. doi: 10.1161/HYPERTENSIONAHA.115.05283

35. de la Sierra A, Pareja J, Armario P, Barrera A, Yun S, Vázquez S, Sans L, Pascual J, Oliveras A. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. *Am J Hypertens*. 1998;11:733–738.

36. Zuern CS, Rizas KD, Eick C, Stoleriu C, Bunk L, Barthel P, Balletshofer B, Gawaz M, Bauer A. Effects of renal sympathetic denervation on 24-hour blood pressure variability. *Front Physiol*. 2012;3:134. doi: 10.3389/fphys.2012.00134

37. Kario K, Bhatt DL, Brar S, Cohen SA, Fahy M, Bakris GL. Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. *Hypertension*. 2015;66:1130–1137. doi: 10.1161/HYPERTENSIONAHA.115.06260

38. Kario K, Böhm M, Mahfoud F, Townsend RR, Weber MA, Patel M, Tyson CC, Weil J, Agdirligolu T, Cohen SA, Fahy M, Kandzari DE. Twenty-four-hour ambulatory blood pressure reduction patterns after renal denervation in the SPYRAL HTN-OFF MED trial. *Circulation*. 2018;138:1602–1604. doi: 10.1161/CIRCULATIONAHA.118.035588

39. Sardar P, Bhatt DL, Kirtane AJ, Kennedy KE, Chatterjee S, Giri J, Soukas PA, White WB, Parikh SA, Aronow HD. Catheter-based renal denervation in patients with hypertension: a meta-analysis of Sham-controlled randomized trials. *J Am Coll Cardiol*. 2019;73:1633–1642.

40. Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Lobo MD, Sharp ASP, Bloch MJ, Basile J, Wang Y, Saxena M, Lurz P, Rader F, Sayer J, Fisher NDL, Fouassier D, Barman NC, Reeves-Stocker H, McClure C, Kirtane AJ. RADIANCE-HTN Investigators. Six-month results of treatment-blinded medication titration for hypertension control following randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO Trial [published online March 17, 2019]. *Circulation*. doi: 10.1161/CIRCULATIONAHA.119.040451

41. Kario K, Yamamoto E, Tomita H, Otuka T, Saito S, Ueno T, Yasuhara D, Shimada K. SYMPLICITY HTN-Japan Investigators. Sufficient and persistent blood pressure reduction in the final long-term results from SYMPLICITY HTN-Japan safety and efficacy of renal denervation at 3 years. *Circ J*. 2019;83:622–629. doi: 10.1253/circj.CJ-18-1018

42. Böhm M, Mahfoud F, Townsend RR, Kandzari DE, Pocock S, Ukena C, Weber MA, Hoshide S, Patel M, Tyson CC, Weil J, Agdirligolu T, Fahy M, Kario K. Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. *Eur Heart J*. 2019;40:743–751. doi: 10.1093/eurheartj/ehy871